What is the 13F Pro Quality Score for ADMA?

13F Pro ranks ADMA BIOLOGICS, INC. (ADMA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADMA's current score at https://13fpro.ai/research/ADMA (free sign-up required for the full ranking).

Which hedge funds own the most ADMA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ADMA include BlackRock,, STATE STREET, Capital Research Global Investors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ADMA as soon as new 13F filings post.

Where does 13F Pro source ADMA data?

All ADMA BIOLOGICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ADMA BIOLOGICS, INC. files with the SEC under CIK 1368514. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADMA in?

ADMA BIOLOGICS, INC. (ADMA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ADMA's revenue?

Per ADMA BIOLOGICS, INC.'s latest 10-Q filed with the SEC on 2026-05-06, the biggest revenue drivers are: ASCENIV ($97.5M, +27.7% YoY); BIVIGAM ($15.4M, -54.0% YoY); Plasma Collection Centers ($0.7M, -31.8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/ADMA.

What are ADMA's largest expenses?

ADMA BIOLOGICS, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($26.7M, +11.1% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is ADMA research updated on 13F Pro?

ADMA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ADMA BIOLOGICS, INC.(ADMA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1368514 ADMA stock profile & AI dashboard →

13F Pro Quality Score

76.0/100

Rank #113 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.2/100

Profitability

91.8/100

Balance Sheet

97.8/100

Earnings Quality

98.4/100

Free Cash Flow

63.5/100

Institutional Flow

75.4/100

Revenue Scale

36.4/100

Dilution Risk

29.3/100

ADMA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ADMA BIOLOGICS, INC. (ADMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADMA at 76.0/100 on a 32-signal composite quality model, placing it at rank #113 of 2,879 stocks — the top 5% of the AI-ranked universe. ADMA scores in the top quartile across earnings quality (98.4), balance sheet strength (97.8), profitability (91.8). Areas of concern include revenue scale (36.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ADMA BIOLOGICS, INC. reports quarterly revenue of $114.5M, net income of $45.3M, an operating margin of 50.9%. Top institutional holders of ADMA by reported 13-F value include BlackRock,, STATE STREET, Capital Research Global Investors, based on the most recent SEC filings. ADMA trades on the Nasdaq exchange and files with the SEC under CIK 1368514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADMA BIOLOGICS, INC. directly from SEC EDGAR. ADMA BIOLOGICS, INC.'s 13F Pro composite quality score has ranged between 8 and 89 since 2021, currently 76.0 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ADMA BIOLOGICS, INC.

Quirks, history, and lore behind ADMA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · focused on plasma-derived therapeutics · listed on Nasdaq · headquartered in Florida.
2
The Numbers
A small-cap name with annual revenues in the hundreds of millions of dollars — tiny by pharma standards, but growing fast as demand for its products climbs.
3
The History
Founded in the early 2000s, it spent years building out its own plasma collection and manufacturing infrastructure rather than relying on third parties — a capital-heavy bet that took a long time to pay off.
4
The Secret
Its core products treat patients with primary immune deficiencies and other conditions that leave the immune system dangerously under-armed — think intravenous immunoglobulin (IVIG).
5
The Lore
The company owns and operates its own FDA-licensed plasma collection centers and a dedicated manufacturing facility in Boca Raton — a vertically integrated model rare among small biotechs.
6
The Giveaway
Its flagship product BIVIGAM and its portfolio of plasma-derived biologics come from a company whose very name fuses "ADMA" with the business of keeping immune-compromised patients alive.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ADMA's Business? Latest 10-Q Breakdown

AI-extracted from ADMA BIOLOGICS, INC.'s 10-Q filed 2026-05-06 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ASCENIV revenue surged 28% YoY to $97.5M, offsetting 54% BIVIGAM decline from competitive pricing pressure, while gross margin expanded to 70.5% on favorable product mix and yield enhancement benefits.

Biggest Revenue Drivers

Total revenue: $114.5M-0.3% YoY

ASCENIV$97.5M+27.7% YoY

Continued growth in market acceptance and prescriber expansion; FDA approved pediatric label expansion in May 2026 for ages two and older.

BIVIGAM$15.4M-54.0% YoY

Lower volume due to competitive pressures in standard immune globulin industry with new entrants employing aggressive pricing tactics.

Plasma Collection Centers$0.7M-31.8% YoY

Decreased from sale of three plasma collection centers completed in Q1 2026.

Intermediates and other$0.8M-78.5% YoY

Includes Nabi-HB and discontinued sales of certain intermediate products.

Largest Expense Items

Selling, general and administrative$26.7M+11.1% YoY

Higher employee-related costs including $0.8M share-based compensation modification for former CFO departure and increased headcount.

Watch Items from the Filing

Two customers (BioCare and Curascript) represent 71% of Q1 2026 revenues and 82% of accounts receivable; loss of either could materially impact business.
BIVIGAM revenue declined 54% YoY due to aggressive competitive pricing from new IVIG market entrants with extended payment terms, rebates, and discounts beginning H2 2025.
Company repurchased $125M in stock via accelerated share repurchase agreement using revolving credit facility, increasing total debt to $196.9M while maintaining compliance with 2.50x leverage covenant.
FDA approved yield enhancement production process in April 2025 expected to increase ASCENIV and BIVIGAM yields 20%+ from same starting plasma; first full year of benefit anticipated in FY2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$114.5M

Net Income

Q1 2026

$45.3M

Free Cash Flow

Q1 2026

$55.7M

Operating Margin

Q1 2026

50.9%

D/E Ratio

Q1 2026

0.51

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+19.6% YoY

$510.2MFY 2025

FY21 $80.9MFY23 $258.2MFY24 $426.5MFY25 $510.2M

Net Income

-25.7% YoY

$146.9MFY 2025

FY21 $-71.7MFY23 $-28.2MFY24 $197.7MFY25 $146.9M

Operating Income

+37.7% YoY

$191.4MFY 2025

FY21 $-58.4MFY23 $21.6MFY24 $139.0MFY25 $191.4M

EPS (Diluted)

-25.9% YoY

$0.60FY 2025

FY21 $-0.51FY23 $-0.13FY24 $0.81FY25 $0.60

Total Assets

+27.7% YoY

$624.2MFY 2025

FY21 $276.3MFY23 $329.2MFY24 $488.7MFY25 $624.2M

Total Debt

+3.6% YoY

$75.0MFY 2025

FY21 —FY23 —FY24 $72.3MFY25 $75.0M

Op. Cash Flow

-57.5% YoY

$50.4MFY 2025

FY21 $-112.4MFY23 $8.8MFY24 $118.7MFY25 $50.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$510.2M +19.6%	$426.5M +65.2%	$258.2M +219.0%	$80.9M +91.7%	$42.2M +43.9%	$29.3M
Net Income	$146.9M -25.7%	$197.7M +800.0%	$-28.2M +60.6%	$-71.7M +5.4%	$-75.7M -56.9%	$-48.3M
Operating Income	$191.4M +37.7%	$139.0M +542.5%	$21.6M +137.1%	$-58.4M +10.1%	$-64.9M -56.7%	$-41.4M
EPS (Diluted)	$0.60 -25.9%	$0.81 +723.1%	$-0.13 +74.5%	$-0.51 +42.0%	$-0.88	—
Total Assets	$624.2M +27.7%	$488.7M +48.5%	$329.2M +19.2%	$276.3M +33.0%	$207.7M +63.4%	$127.1M
Total Debt	$75.0M +3.6%	$72.3M	—	—	—	$0.00
Operating Cash Flow	$50.4M -57.5%	$118.7M +1248.5%	$8.8M +107.8%	$-112.4M -10.2%	$-102.0M -33.9%	$-76.2M

Get alerted when ADMA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ADMA BIOLOGICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADMA

BlackRock, Inc.
$331.8M36,830,774 sh
STATE STREET CORP
$126.9M14,084,205 sh
Capital Research Global Investors
$100.8M11,191,116 sh
VANGUARD CAPITAL MANAGEMENT LLC
$92.9M10,306,871 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$79.9M8,868,657 sh
Nuveen, LLC
$54.9M6,098,225 sh
GEODE CAPITAL MANAGEMENT, LLC
$52.5M5,824,116 sh
CITADEL ADVISORS LLC
$52.4M5,810,642 sh
DIMENSIONAL FUND ADVISORS LP
$45.1M5,005,481 sh
AMERICAN CENTURY COMPANIES INC
$43.1M4,789,011 sh

Fund	Value	Shares
BlackRock, Inc.	$331.8M	36,830,774
STATE STREET CORP	$126.9M	14,084,205
Capital Research Global Investors	$100.8M	11,191,116
VANGUARD CAPITAL MANAGEMENT LLC	$92.9M	10,306,871
VANGUARD PORTFOLIO MANAGEMENT LLC	$79.9M	8,868,657
Nuveen, LLC	$54.9M	6,098,225
GEODE CAPITAL MANAGEMENT, LLC	$52.5M	5,824,116
CITADEL ADVISORS LLC	$52.4M	5,810,642
DIMENSIONAL FUND ADVISORS LP	$45.1M	5,005,481
AMERICAN CENTURY COMPANIES INC	$43.1M	4,789,011

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADMA on your watchlist

Track score changes the day ADMA BIOLOGICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADMA a good stock to buy?

13F Pro's AI-powered analysis of ADMA BIOLOGICS, INC. (ADMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADMA are available on the ADMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ADMA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADMA BIOLOGICS, INC.'s investment landscape.